Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**RNA, U6 small nuclear 239, pseudogene (RNU6-239P)** is a human gene classified as a pseudogene of the U6 small nuclear RNA gene family[2]. U6 snRNA genes encode non-coding RNAs that are core components of the spliceosome and highly conserved across evolution[1][3]. However, RNU6-239P specifically is a pseudogene, meaning it is a non-functional genomic relic originally derived from a functional U6 snRNA gene. Pseudogenes such as RNU6-239P generally do not produce active RNA or protein products, have no known biological activity, and are not considered valid therapeutic targets. Their presence reflects the proliferation and evolutionary divergence of the U6 snRNA gene family in primate and vertebrate genomes; many copies exist, both functional and pseudogenic, on the human genome[1][2]. There is no evidence linking RNU6-239P to human disease, drug interaction, or use as a biomarker or therapeutic target[2][5]. Its sequence provides evidence for evolutionary mechanisms such as duplication and mutation but otherwise has no direct significance in cell biology or medicine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 239, pseudogene (RNU6-239P).